Immediate Impact

2 by Nobel laureates 13 from Science/Nature 66 standout
Sub-graph 1 of 22

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout

Works of Frank Herting being referenced

Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388)
2016
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
2013

Author Peers

Author Last Decade Papers Cites
Frank Herting 314 177 193 229 28 700
Giovanni Citterio 250 115 64 337 36 842
Patrick B. Lappin 286 53 126 174 26 660
Rosa I. Gallagher 410 140 158 341 27 792
Milos J. Janicek 171 138 99 295 18 583
Y. Terui 328 71 55 206 28 674
Maxim Kebenko 240 61 101 260 29 590
Carsten Dan Ley 299 173 136 115 25 707
Glenn Michelson 333 78 76 278 50 649
Ivan Inigo 219 111 87 357 21 675
Shenghua Wen 392 40 108 198 21 603

All Works

Loading papers...

Rankless by CCL
2026